The Future of Biosimilars: Boom or Bust

Recent legislation has provided a faster path to market for biologics which are positioned to revolutionize the field of protein therapeutics. HRA® coupled clinical, regulatory, and survey information with the economics of biosimilars to improve understanding and critical thinking in the field. HRA® conducted an online survey with 160 Rheumatologists and Oncologists designed to yield insights into potential drivers of biosimilar prescribing.

This webinar can help you answer questions, such as:
  • Is there really a potential for cost-saving with biosimilars?
  • Will this be a competitive space?
  • What are physician attitudes towards biosimilars versus biologics?
  • What are the key drivers of physician’s uptake of biosimilars?
  • When will physicians be confident in biosimilars?
Benefits:
  • Gain knowledge of the competitive landscape today and what it could be tomorrow
  • Position your biosimilar for success
  • Craft successful physician messaging for your marketing campaigns
  • Use this research to jumpstart on your competitive intelligence business objectives
Copyright HRA Data Driven Intelligence 1974-2018 HRA Data Driven Intelligence, LLC. All rights Reserved.
^